OBJECTIVES: To determine whether infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) occurred after two potential episodes of exposure through needle- and syringe-sharing in Australian prisons, and to examine use of post-exposure prophylaxis (PEP) against HIV infection in the prison setting. DESIGN: Cohort study of potential contacts of two prisoners infected with HIV, HBV and HCV followed up for up to 14 months. SETTING: Two Australian prisons between November 2000 (time of exposure) and December 2001. PARTICIPANTS: Two index patients (both infected with HIV and HCV; one also infectious for HBV) from two different prisons, and 104 inmates who shared needles and syringes. MAIN OUTCOME MEASURES: Seroconversions to HIV, HBV and HCV related to the high-risk exposure and uptake and completion of HIV PEP determined from medical records of inmates. RESULTS: There were four seroconversions to HCV within 14 months of the potential exposure (14% of those susceptible in the cohort), but no recorded HIV or HBV seroconversions. Forty-six inmates (82% of those eligible) were offered PEP, and 34 of these (74%) elected to receive it. Only eight (24% of the 34) completed the full PEP course. CONCLUSIONS: HCV transmission in the prison setting is related to high-risk needle- and syringe-sharing. Administering HIV PEP in the prison setting is complicated by challenging risk assessment and follow-up.
OBJECTIVES: To determine whether infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) occurred after two potential episodes of exposure through needle- and syringe-sharing in Australian prisons, and to examine use of post-exposure prophylaxis (PEP) against HIV infection in the prison setting. DESIGN: Cohort study of potential contacts of two prisoners infected with HIV, HBV and HCV followed up for up to 14 months. SETTING: Two Australian prisons between November 2000 (time of exposure) and December 2001. PARTICIPANTS: Two index patients (both infected with HIV and HCV; one also infectious for HBV) from two different prisons, and 104 inmates who shared needles and syringes. MAIN OUTCOME MEASURES: Seroconversions to HIV, HBV and HCV related to the high-risk exposure and uptake and completion of HIV PEP determined from medical records of inmates. RESULTS: There were four seroconversions to HCV within 14 months of the potential exposure (14% of those susceptible in the cohort), but no recorded HIV or HBV seroconversions. Forty-six inmates (82% of those eligible) were offered PEP, and 34 of these (74%) elected to receive it. Only eight (24% of the 34) completed the full PEP course. CONCLUSIONS:HCV transmission in the prison setting is related to high-risk needle- and syringe-sharing. Administering HIV PEP in the prison setting is complicated by challenging risk assessment and follow-up.
Authors: Bruno Fernandes de Oliveira Santos; Nathalie Oliveira de Santana; Alex Vianey Callado Franca Journal: World J Gastroenterol Date: 2011-07-07 Impact factor: 5.742
Authors: Kate Dolan; Suzy Teutsch; Nicolas Scheuer; Michael Levy; William Rawlinson; John Kaldor; Andrew Lloyd; Paul Haber Journal: Eur J Epidemiol Date: 2010-02 Impact factor: 8.082
Authors: Jennifer A Gates; Jeffrey J Post; John M Kaldor; Yong Pan; Paul S Haber; Andrew R Lloyd; Kate A Dolan Journal: J Urban Health Date: 2004-09 Impact factor: 3.671
Authors: Suzy Teutsch; Fabio Luciani; Nicolas Scheuer; Luke McCredie; Parastu Hosseiny; William Rawlinson; John Kaldor; Gregory J Dore; Kate Dolan; Rosemary Ffrench; Andrew Lloyd; Paul Haber; Michael Levy Journal: BMC Public Health Date: 2010-10-22 Impact factor: 3.295
Authors: Giuseppe La Torre; Luca Miele; Giacomina Chiaradia; Alice Mannocci; Manuela Reali; Giovanni Gasbarrini; Elisabetta De Vito; Antonio Grieco; Walter Ricciardi Journal: BMC Infect Dis Date: 2007-08-30 Impact factor: 3.090